



Buprenorphine is a medication used to treat opioid use disorder (OUD) and is classified as a Schedule III controlled substance. As of 2025, the federal DATA-waiver (X-waiver) requirement to prescribe buprenorphine has been eliminated, allowing any practitioner with a DEA registration including Schedule III authority to prescribe it for OUD without additional training or certification.

However, state laws vary significantly, with some states maintaining certain restrictions such as mandatory counseling, drug testing, dosage limits, and prescription length. Telemedicine prescribing of buprenorphine is allowed under new DEA rules effective February 18, 2025, which enable remote prescribing with identity verification and certain safeguards. Patients can receive up to a 6-month supply via telehealth with subsequent prescriptions requiring in-person visits.

Buprenorphine prescribing practitioners must comply with both federal DEA regulations and applicable state laws, including any requirements for licensing or program participation. Programs expanding substance use disorder treatments may require state-specific licensure.

In summary, buying buprenorphine online with limited stock in 2025 is possible through licensed healthcare providers who have DEA Schedule III authority, abiding by federal and state rules on prescribing, telemedicine, and patient monitoring. Secure, legal purchase requires valid prescriptions dispensed by authorized pharmacies ensuring safety and compliance